Hyperice Unveils Normatec Elite Heat Legs for Enhanced Muscle Recovery
November 9, 2026
The combination of both heat and compression drives the therapeutic benefits deeper into the legs for a more amplified experience
The combination of both heat and compression drives the therapeutic benefits deeper into the legs for a more amplified experience
BREA, Calif., Nov. 3, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, today announced U.S. FDA clearance of the Access MeMed BV® assay, a rapid host-response blood test that helps clinicians distinguish bacterial from viral infections in adult and pediatric patients. Available on the DxI 9000 and Access 2 immunoassay analyzers already installed in hospital laboratories nationwide, the new assay provides timely information aiding treatment decisions without requiring new instrumentation or changes to existing testing workflows. On the DxI 9000 Analyzer, results are available in as little as 15 minutes.
A new study led by King’s College London has found that chemotherapy helps attract a specific population of immune cells called stem-like T cells toward tumors.
A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
PARSIPPANY, N.J., Nov. 6, 2026 /PRNewswire/ — Onkos Surgical, Inc. today announced a new FDA 510(k) clearance for its NanoCept® Antibacterial Technology, expanding its application to a broader offering of titanium components in the ELEOS™ Limb Salvage System. This marks another milestone in the company’s continued investment in antibacterial innovation.
Adelaide University researchers have found a DNA “switch” that helps the body stop the growth of the most common form of breast cancer, providing new insights that could help with future treatments
The current standard of care involves the use of temozolomide (TMZ), a chemotherapy medication. However, the tumor can be difficult to control because cancer cells evolve to evade the effects of such treatments. Thus, finding new ways to target these cells is an important area in cancer research.
Smartwatches may be able to detect hypertension (high blood pressure) with the help of an artificial intelligence (AI) system that interprets sensor readings, a paper in Nature reports.
Evident Vascular has announced U.S. Food and Drug Administration 510(k) clearance for the Evident Vascular Guidance System and Evident peripheral imaging catheters. The Guidance System is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions.
BELFAST, Northern Ireland, Nov. 5, 2026 /PRNewswire/ –PulseAI, a medical technology company developing artificial intelligence for cardiac diagnostics, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its AI-powered arrhythmia analysis model for wearables.